Description
An iridoid glycoside with diverse biological activities; increases cell viability and migration of BM-EPCs from 0.1-1,000 μM; inhibits apoptosis and reduces levels of MMP-3 and MMP-13 in chondrocytes; inhibits LPS-induced nuclear translocation of NF-κB and reduces COX-2, iNOS, NF-α, and IL-1β mRNA expression in RAW 264.7 cells; reduces colonic MPO activity, COX-2 and iNOS mRNA expression, and disease severity in a mouse model of DSS-induced ulcerative colitis at 100 and 200 mg/kg; increases bone mineral content, bone mineral density, and improves bone microstructure in ovariectomized mice at 40 and 80 mg/kg; reduces acetic acid-induced writhing in mice and carrageenan-induced paw edema in rats at 20 and 30 mg/kg; decreases macrophage infiltration and wound healing time and increases blood vessel formation in a rat model of wound healing
Formal name: (1S,4aS,7R,7aS)-1-(β-D-glucopyranosyloxy)-1,4a,7,7a-tetrahydro-7-hydroxy-7-(hydroxymethyl)-cyclopenta[c]pyran-4-carboxylic acid
Synonyms: NSC 291303|NSC 88926
Molecular weight: 390.3
CAS: 5945-50-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Natural Products|Glycosides||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Neuroscience|Pain Research
